Boston Scientific gained FDA approval for Farapulse in January 2024. Image credit: Michael Vi via Shutterstock.com.

波士顿科学公司于2024年1月获得Farapulse的FDA批准。图片来源：Michael Vi通过Shutterstock.com。

Boston Scientific has raised its 2025 profit outlook to between $2.95 and $2.99 per share amid strong Q2 performance in its cardiovascular unit, driven in large part by the uptake of its Farapulse pulsed field ablation (PFA) system.

波士顿科学公司将其2025年的利润预期上调至每股2.95至2.99美元，这得益于其心血管部门在第二季度的强劲表现，其中很大程度上是由其Farapulse脉冲场消融（PFA）系统的应用推动的。

The company now anticipates an adjusted profit of $2.95 to $2.99 per share for 2025, raising its previous guidance of $2.87 to $2.94.

公司现在预计2025年每股调整后利润为2.95至2.99美元，高于之前预测的2.87至2.94美元。

Boston Scientific’s financials revealed total sales of more than $5bn in Q2 2025, representing a 22.8% rise on Q2 2024 at $4.12bn, with shares in the company rising by over 4% following the result’s announcement.

波士顿科学公司的财务数据显示，2025年第二季度总销售额超过50亿美元，较2024年第二季度的41.2亿美元增长了22.8%，公司股价在业绩公布后上涨超过4%。

The majority of the quarter’s profits emanated from the US-based company’s cardiovascular unit at $3.34bn – representing a 26.8% increase on the unit’s Q2 2024 performance at $2.63bn.

本季度的大部分利润来自这家美国公司的心血管部门，达到33.4亿美元——较该部门2024年第二季度的26.3亿美元增长了26.8%。

GlobalData medical analyst David Beauchamp noted that since its emergence, PFA has displaced most other approaches to treating atrial fibrillation (AFib) such as radiofrequency (RF) and cryoablation. Meanwhile, Boston Scientific only has competition in the space from Medtronic and Johnson & Johnson (J&J)..

GlobalData医疗分析师David Beauchamp指出，自从PFA出现以来，它已经取代了大多数其他治疗心房颤动（AFib）的方法，如射频（RF）和冷冻消融。同时，波士顿科学公司在此领域仅面临来自美敦力和强生（J&J）的竞争。

Boston Scientific gained US Food and Drug Administration (FDA) approval on Farapulse in January 2024, a month after Medtronic’s approval for its PulseSelect PFA system. J&J secured approval for its Varipulse PFA system in November 2024.

波士顿科学公司于2024年1月获得美国食品药品监督管理局（FDA）对Farapulse的批准，这比美敦力公司PulseSelect PFA系统的批准晚了一个月。强生公司则于2024年11月获得了其Varipulse PFA系统的批准。

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会反应还是预见？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

由GlobalData提供

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

Beauchamp said: “Boston Scientific also has had widespread success with their WATCHMAN series of left atrial appendage closure devices.

博彻姆说：“波士顿科学公司的 WATCHMAN 系列左心耳封堵器也取得了广泛的成功。

“It’s not shocking to see them increasing their profit expectations, as they have been consistently successful for years and their device quality is very high.”

“看到他们提高盈利预期并不令人震惊，因为他们多年来一直非常成功，而且他们的设备质量非常高。”

Elsewhere across the business, Boston Scientific reported a 26.9% rise to $676m in its urology unit, up from $525m in Q2 2024. The company’s peripheral intervention division also saw a significant increase of 18.3% to $698m versus $590m in Q2 2024.

波士顿科学公司其他业务方面，其泌尿科部门报告收入增长了26.9%，达到6.76亿美元，高于2024年第二季度的5.25亿美元。公司的外周介入部门也实现了显著增长，收入增长18.3%至6.98亿美元，而2024年第二季度为5.9亿美元。

Boston Scientific’s chairman and CEO Mike Mahoney commented: “This was another excellent quarter – marked by exceptional top-line performance – that delivered margin expansion and prioritised investment for future growth.”

波士顿科学公司的董事长兼首席执行官迈克·马奥尼评论道：“这是另一个出色的表现季度——以卓越的顶级业绩为标志——实现了利润空间的扩大，并优先投资于未来的增长。”

Reflecting on the quarter during an earnings call with analysts, the company’s CFO John Monson said that sales for medical device makers such as Boston Scientific had been boosted due to a growth in surgical procedures, thereby helping ameliorate broader concerns about healthcare spending concerning the Trump administration’s proposed tariffs..

在与分析师的财报电话会议上，该公司首席财务官约翰·蒙森表示，由于外科手术数量的增长，波士顿科学等医疗设备制造商的销售得到了提振，从而有助于缓解围绕特朗普政府拟议关税对医疗支出的更广泛担忧。

However, Monson commented: “Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100m, down from a $200m estimate.”

然而，蒙森评论道：“根据当前的预期关税时间表，我们现在预计全年将面临约1亿美元的不利影响，低于此前估计的2亿美元。”

According to GlobalData analysis, months after the approval of Farapulse and Medtronic’s PulseSelect, physicians in the US had already started displaying a

根据 GlobalData 分析，在 Farapulse 和美敦力 PulseSelect 获批数月后，美国的医生已经开始展示出

much stronger preference for Farapulse over PulseSelect.

对Farapulse的偏好远强于PulseSelect。

J&J also released its

强生公司还发布了其

Q2 2025 financials last week

2025年第二季度财务数据上周发布

, reporting a 7.3% rise in its Medtech unit on Q2 2024 to around $8.54m. Since its FDA approval in 2024, J&J’s Varipulse PFA system has clearly had an effect on the Medtech unit’s performance, albeit to a lesser extent than Farapulse given that Boston Scientific’s PFA system has had a slight head start in the market..

，报告称其医疗科技部门在2024年第二季度增长了7.3%，达到约854万美元。自2024年获得FDA批准以来，强生的Varipulse PFA系统显然对医疗科技部门的表现产生了影响，尽管影响程度不及Farapulse，因为波士顿科学公司的PFA系统在市场上稍微领先一步。

Sign up for our daily news round-up!

注册获取我们的每日新闻汇总！

Give your business an edge with our leading industry insights.

利用我们领先的行业洞察，为您的业务提供优势。

Sign up

注册

Medical Device Network Excellence Awards - The Benefits of Entering

医疗器械网络卓越奖——参赛的好处

Gain the recognition you deserve! The

获得你应得的认可！

Medical Device Network Excellence Awards

医疗器械网络卓越奖

celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

庆祝创新、领导力和影响力。通过参赛，您将展示您的成就，提升行业形象，并将自己置于推动医疗器械进步的顶级领导者之列。不要错过脱颖而出的机会——立即提交您的参赛作品！

Nominate Now

立即提名

Share

分享

Copy Link

复制链接

Share on X

分享到X

Share on Linkedin

分享到领英

Share on Facebook

分享到 Facebook